SOLE (Study of Letrozole Extension):A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer
Breast cancer prevention – significant progress: 49% reduction in breast cancer occurrence with anastrozole (long-term follow up results of the IBIS II Prevention trial)